The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Income (loss) from continuing operations | 27,274 |
| Depreciation and amortization | 47,011 |
| Provision (benefit) for expected credit losses | 1,256 |
| Equity-based compensation | 12,673 |
| Change in fair value of contingent consideration | 0 |
| Impairments of assets | 0 |
| Loss on extinguishment | -326 |
| Loss on disposals | -81 |
| Deferred income taxes | -909 |
| Unrealized (gain) loss on foreign currency fluctuations | 360 |
| Other, net | 1,161 |
| Accounts receivable | 916 |
| Inventory | -8,569 |
| Accounts payable and accrued expenses | -19,814 |
| Other current and noncurrent assets and liabilities | 1,679 |
| Net cash from operating activities - continuing operations | 74,673 |
| Net cash from operating activities - discontinued operations | 0 |
| Net cash from operating activities | 74,673 |
| (settlement) proceeds from the sale of a business | -686 |
| Purchase of property and equipment | 2,562 |
| Investments and acquisition of distribution rights | 0 |
| Net cash from investing activities - continuing operations | -3,248 |
| Net cash from investing activities - discontinued operations | 0 |
| Net cash from investing activities | -3,248 |
| Proceeds from issuance of class a and b common stock | 2,074 |
| Tax withholdings on equity-based compensation | 9 |
| Receipt of deferred consideration | 0 |
| Payment of contingent consideration | 19,771 |
| Borrowing on revolver | 45,000 |
| Payment on revolver | 45,000 |
| Proceeds from the issuance of long-term debt, net of discount | 31,907 |
| Payments on the extinguishment of long-term debt | 65,765 |
| Debt financing costs | 697 |
| Payments on long-term debt | 9,052 |
| Other, net | -827 |
| Net cash from financing activities | -62,140 |
| Effect of exchange rate changes on cash | 371 |
| Net change in cash and cash equivalents | 9,656 |
| Cash and cash equivalents at the beginning of the period | 41,582 |
| Cash and cash equivalents at the end of the period | 51,238 |
Bioventus Inc. (BVS)
Bioventus Inc. (BVS)